Researchers unveiled an engineered vesicular stomatitis virus variant, ErbB-OSV, designed to selectively target and kill metastatic ovarian cancer cells via rewired signaling while sparing normal tissue. The work compares the safety profile and potency against the attenuated VSV-ON-∆M51 strain, with the authors positioning ErbB-OSV as a next-generation candidate for metastatic disease. The approach builds on oncolytic virus engineering by incorporating tumor-directed selectivity, an effort aimed at improving therapeutic windows that have limited translation for earlier viral platforms. For the field, engineered oncolytics remain one of the most active areas of experimentation at the interface of virotherapy and precision targeting, where efficacy will be judged by tumor selectivity, immune activation quality, and tolerability in follow-on translational studies.